Big Brand Fights Come To India As Januvia, Galvus And Onglyza Vie For Market Share
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Marketing of patented and branded drugs is a relatively new concept in India but going by the initial strategies put into play by multinational companies - most notably for the DPP-4 inhibitors Januvia (sitagliptin), Galvus (vildagliptin) and Onglyza (saxagliptin) - it has all the ingredients of blowing up into an all out war in the race to capture the mind recall of doctors
You may also be interested in...
Pinning Hopes On A Wider Offering, Boehringer-Lilly Launch DPP-4 Trajenta In A Crowded India Market
A 30% annual growth in the anti-diabetes market is fueling new launches in India, but competition is getting tougher.
Asia Spotlight: India Case Study – Novartis’ Galvus Inches Closer To Merck’s Januvia As Battle For Brand Supremacy Rages On
Three years after Novartis and MSD launched their DPP-4 inhibitors in India, PharmAsia News takes a closer look at who will come out on top.
India Case Study: Novartis’ Galvus Inches Closer To Merck’s Januvia As Battle For Brand Supremacy Rages On
Three years after Novartis and MSD launched their DPP-4 inhibitors in India, PharmAsia News takes a closer look at who will come out on top.